- $2.05bn
- $2.13bn
- $120.25m
Brief: Mesoblast Says Mesoblast Cell Therapy Products Not Subject To U.S. Tariffs
Brief: Mesoblast Says Allogeneic Cell Therapy Products Are Designated ‘U.S. Country Of Origin’ And Not Subject To U.S. Tariffs
Brief: Mesoblast Says Co Entered Medicaid National Drug Rebate Agreement With US CMS For Ryoncil
ASX-listed Mesoblast climbs on Ryoncil pricing information release
Mesoblast tumbles as biotech firm starts trading as part of Australian benchmark index
Brief: Mesoblast Added To S&P Asx200 Index
Brief: Mesoblast Says HY Loss Attributable $47.9 Million
Brief: Mesoblast Ltd Files Prospectus Relates To Offer And Sale Of Up To 34.7 Million Ordinary Shares
Brief: Mesoblast Says Raises A$260 Million For Ryoncil Commercial Launch
Australia's Mesoblast slides on discounted placement
Brief: Mesoblast Ltd Seeks Trading Halt
Mesoblast gains on FDA nod for graft-versus-host disease cell therapy
Australia's Mesoblast at 4-yr high on US FDA nod for cell therapy
Brief: FDA Approves First Mesenchymal Stromal Cell Therapy To Treat Steroid-Refractory Acute Graft-Versus-Host Disease
US FDA approves Mesoblast's cell therapy for graft-versus-host disease (updated)
US FDA approves Mesoblast's cell therapy for graft-versus-host disease
Brief: Mesoblast To Be Added To Nasdaq Biotechnology Index
Brief: Mesoblast Says FDA Grants Mesoblast RMAT Designation
Australia's Mesoblast jumps most in 2 months on capital raise